Literature DB >> 33771354

A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2.

Marco P Licciardello1, Paul Workman2.   

Abstract

Casein kinase 2 (CK2) is highly expressed in cancer and has been considered a potential therapeutic target. Wells and colleagues developed and characterized the new CK2 inhibitor SGC-CK2-1. Unexpectedly, this potent and highly selective chemical probe does not show broad antiproliferative activity in cancer cells.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; cancer; drug target; neurodegenerative diseases; protein kinase; selective CK2 inhibitor

Year:  2021        PMID： 33771354     DOI： 10.1016/j.tips.2021.02.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  4 in total

Review 1.  CK2 and the Hallmarks of Cancer.

Authors:  May-Britt Firnau; Angela Brieger
Journal:  Biomedicines       Date:  2022-08-16

Review 2.  Protein kinase CK2 - diverse roles in cancer cell biology and therapeutic promise.

Authors:  Janeen H Trembley; Betsy T Kren; Muhammad Afzal; George A Scaria; Mark A Klein; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2022-09-17       Impact factor: 3.842

3.  CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(-) HNSCC Cell Lines.

Authors:  Janeen H Trembley; Bin Li; Betsy T Kren; Amy A Gravely; Emiro Caicedo-Granados; Mark A Klein; Khalil Ahmed
Journal:  Biomedicines       Date:  2021-05-18

4.  SGC-CK2-1 Is an Efficient Inducer of Insulin Production and Secretion in Pancreatic β-Cells.

Authors:  Mandy Pack; Claudia Götz; Selina Wrublewsky; Mathias Montenarh
Journal:  Pharmaceutics       Date:  2021-12-22       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.